(NASDAQ: TENX) Tenax Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.76%.
Tenax Therapeutics's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast TENX's revenue for 2023 to be $111,740,550, with the lowest TENX revenue forecast at $111,740,550, and the highest TENX revenue forecast at $111,740,550. On average, 1 Wall Street analysts forecast TENX's revenue for 2024 to be $167,610,825, with the lowest TENX revenue forecast at $167,610,825, and the highest TENX revenue forecast at $167,610,825.
In 2025, TENX is forecast to generate $251,416,238 in revenue, with the lowest revenue forecast at $251,416,238 and the highest revenue forecast at $251,416,238.